An existing Alzheimer’s medication slashes inflammation and insulin resistance in patients with metabolic syndrome, a potential therapeutic intervention for a highly dangerous condition affecting 30 percent of adults in the United States, according to new clinical trial results by scientists at Northwell Health’s Feinstein Institute for Medical Research.
In a study released in JCI Insight, Feinstein Institute researchers found that the FDA-approved Alzheimer’s drug “galantamine” cut key markers of inflammation – a hallmark of metabolic syndrome – by more than 25 percent, leading to reduced insulin resistance. A cluster of four risk factors – increased blood pressure, a high blood sugar level, excess body fat around the waist and abnormal cholesterol levels – comprise metabolic syndrome, which greatly raises risks for cardiovascular disease and type 2 diabetes.
2 Likes